These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 38784343)
1. Optical Coherence Tomography-Based Positive Predictors of Eplerenone Therapy in Chronic Central Serous Chorioretinopathy: A Retrospective Study. Sahu V; Nayak S; Kumar A; Kashyap H Cureus; 2024 Apr; 16(4):e58791. PubMed ID: 38784343 [TBL] [Abstract][Full Text] [Related]
2. Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy. Borrelli E; Zuccaro B; Zucchiatti I; Parravano M; Querques L; Costanzo E; Sacconi R; Prascina F; Scarinci F; Bandello F; Querques G J Clin Med; 2019 Aug; 8(9):. PubMed ID: 31443376 [No Abstract] [Full Text] [Related]
3. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785 [TBL] [Abstract][Full Text] [Related]
4. Oral eplerenone for the management of chronic central serous chorioretinopathy. Singh RP; Sears JE; Bedi R; Schachat AP; Ehlers JP; Kaiser PK Int J Ophthalmol; 2015; 8(2):310-4. PubMed ID: 25938046 [TBL] [Abstract][Full Text] [Related]
5. Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy. Gergely R; Kovács I; Récsán Z; Sándor GL; Czakó C; Nagy ZZ; Ecsedy M Sci Rep; 2020 Oct; 10(1):16621. PubMed ID: 33024222 [TBL] [Abstract][Full Text] [Related]
6. Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy. Fasler K; Gunzinger JM; Barthelmes D; Zweifel SA Front Pharmacol; 2021; 12():675295. PubMed ID: 34040534 [No Abstract] [Full Text] [Related]
7. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy. Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972 [TBL] [Abstract][Full Text] [Related]
8. [Eplerenone treatment in chronic central serous chorioretinopathy]. Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892 [TBL] [Abstract][Full Text] [Related]
9. Eplerenone Treatment in Chronic Central Serous Chorioretinopathy. Iqbal F; Iqbal K; Inayat B; Arjumand S; Ghafoor Z; Sattar W; Abbas K Cureus; 2021 Oct; 13(10):e18415. PubMed ID: 34729255 [TBL] [Abstract][Full Text] [Related]
10. Eplerenone for treatment of chronic central serous chorioretinopathy. Fraenkel D; Suffo S; Langenbucher A; Seitz B; Abdin AD Eur J Ophthalmol; 2021 Jul; 31(4):1885-1891. PubMed ID: 32854564 [TBL] [Abstract][Full Text] [Related]
11. Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study. Rajesh B; Agrawal H; Peguda HK; Chhablani J Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):479-486. PubMed ID: 30021034 [TBL] [Abstract][Full Text] [Related]
12. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients. Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085 [TBL] [Abstract][Full Text] [Related]
13. Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study. Moein HR; Bierman LW; Novais EA; Moreira-Neto C; Baumal CR; Rogers A; Duker JS; Witkin AJ Int J Retina Vitreous; 2019; 5():39. PubMed ID: 31516734 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal injections with anti-VEGF agent aflibercept versus subthreshold micropulse laser for chronic central serous chorioretinopathy: the alternative treatment regimens for verteporfin-shortage in China. Zhao T; Li J; Wang Y; Guo X; Sun Y Ann Med; 2023 Dec; 55(1):2227424. PubMed ID: 37382371 [TBL] [Abstract][Full Text] [Related]
15. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience. Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056 [TBL] [Abstract][Full Text] [Related]
17. Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy. Li M; Qu J; Liang Z; Tang J; Hu J; Yao Y; Jin E; Li X; Zhao M Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2175-2182. PubMed ID: 35024912 [TBL] [Abstract][Full Text] [Related]
18. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864 [TBL] [Abstract][Full Text] [Related]
19. The Effect of Eplerenone in Chronic Central Serous Chorioretinopathy Refractory to Photodynamic Therapy. Karagiannis D; Parikakis E; Kontomichos L; Batsos G; Chatziralli I Semin Ophthalmol; 2019; 34(6):436-441. PubMed ID: 31309849 [No Abstract] [Full Text] [Related]
20. Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report. Venkatesh R; Pereira A; Jain K; Yadav NK BMC Ophthalmol; 2020 Jun; 20(1):219. PubMed ID: 32503484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]